Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 6/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.54 |
| ▸ | WIZ | O95785 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24696750 | 1.00 | CRBN (0.57) | CRBNMAPTIKZF2WIZ | |
| SCHEMBL25087626 | 0.94 | CRBN (0.61) | CRBNIKZF2WIZ | |
| SCHEMBL26299161 | 0.90 | CRBN (0.60) | CRBNMAPTIKZF2WIZ | |
| SCHEMBL24789294 | 0.88 | IKZF2 (0.52) | CRBNMAPTIKZF2WIZ | |
| SCHEMBL29648417 | 0.87 | CRBN (0.62) | CRBNMAPTIKZF2WIZ | |
| SCHEMBL29648275 | 0.87 | CRBN (0.62) | CRBNMAPTIKZF2WIZ | |
| SCHEMBL24696747 | 0.87 | CRBN (0.62) | CRBNMAPTIKZF2WIZ | |
| SCHEMBL24501550 | 0.87 | CRBN (0.62) | CRBNMAPTIKZF2WIZ | |
| SCHEMBL23267660 | 0.86 | CRBN (0.62) | CRBNIKZF2WIZ | |
| SCHEMBL25988439 | 0.85 | CRBN (0.70) | CRBNIKZF2WIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3835298-B1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20210221802-A1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-07-22 | — | — | US | disclosed |
| WO-2021118629-A1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-06-17 | — | — | WO | disclosed |
| US-10800770-B1 | Chroman derivatives having estrogen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800770-B1 | Chroman derivatives having estrogen receptor degradation activity and uses thereof | ESR1, ESR2, ESRRG | CRBN 280/4885MAPT 4487/4885IKZF2 3330/4885 |
| US-20210221802-A1 | NOVEL CHROMAN DERIVATIVES HAVING ESTROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ESR2, ESR1, ESRRG | CRBN 324/4885MAPT 4508/4885IKZF2 3471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.